| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
24009 |
| Drug |
Nivolumab+relatlimab |
| Brand |
Opdualag® |
| Indication |
Nivolumab+relatlimab (Opdualag® ) is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%. |
| Rapid review commissioned |
05/03/2024 |
| Rapid review completed |
16/04/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab+relatlimab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/05/2024 |
| Pre-submission consultation with Applicant |
13/03/2025 |
